Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board

3 hours ago

Turning focus to clinical work, Verastem axes 31 jobs, scales back cancer drug promotion after disappointing sales

1 hour ago

UPDATED: Biogen makes another bold Alzheimer’s bet, dropping $350M upfront to partner with genome-editing focused ...

16 hours ago

After the field left her behind, a scientist-turned-investor gets her first R&D job; Nouscom finds new leadership for ...

21 minutes ago

Latest

Most read

A 9/11-era Omaha facility, an old Ebola drug, and the ubiquitous Dr. Fauci: Inside the first US novel coronavirus ...

Yesterday

Sage confirms suspension of 2 depression trials after PhIII flop; Esperion follows up maiden approval with combo OK

31 minutes ago

Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO

4 hours ago

UPDATED: A name emerges out of the Gilead M&A rumor mill, and it’s a cancer biotech

16 hours ago

UPDATED: Biohaven scores CGRP OK for acute migraine — can the commercial team catch up with Allergan on its debut?

17 hours ago

Another hiccup for GW Pharma's seizure drug rival, as Zogenix discloses FDA review delay

Yesterday

see latest stream

People

Spark loses another top exec in the wake of $4.3B takeover by Roche — report

Yesterday

Gene therapy pioneer Kathy High has left Spark after completing $4.3B union with Roche

Last week

Fresh off $100M round, GV-backed real-world data startup woos Duke researcher as CMO

Last week

Startups

SoftBank's newest, $165M biotech investment looks for infectious traces in the blood

3 days ago

Animal health vet Juergen Horn makes new antibody play for pets, raking $15M in Series A haul

4 days ago

Drug discovery in HD: Oxford spinoff's mass spectrometry approach scores fresh funding

Last week

Deals

Will a 'risk-off' mindset hasten cell therapy M&A? Iovance surges on buyout chatter

2 days ago

Takeda swoops in to buy little biotech partner and its celiac drug poised to 'change standard of care'

2 days ago

Bicycle Therapeutics takes Roche's Genentech on an up to $2B immuno-oncology ride

3 days ago

IPOs

As sickle cell patients find new options, NEA-founded Imara pitches mid-stage alternative for $86M IPO

Last week

The RAS rush: Revolution Medicines bags remarkable $238M IPO raise, more than doubling original goal

3 weeks ago

Party on: Base editing startup, computational drug discovery experts and CRO bag close to $2B total on their way to ...

4 weeks ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW

Subscribe to Endpoints News

Premium storiesSee all

The top 100 biopharma venture investors at the megabillions deal table

Last week

The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019

3 weeks ago

Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects

3 weeks ago

The power of precedent: How a one-off decision by Janet Woodcock established an unintended fast pathway at the FDA ...

4 weeks ago

Don't missSee all

'The headlines are the headlines, but': BioMarin talks up potential savings as hemophilia gene therapy launch looms

Yesterday

In at least one life-sci hub, gender and diversity initiatives haven’t made a dent

2 days ago

Microbiome Q&A: New study maps the vagina's 'optimal microbiota' — and its implications for biopharma

2 days ago

Theft victim or data bully? IQVIA exchanges blows with small rival it says destroyed evidence in legal fight

2 days ago

Endpoints Standouts

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

Last month

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

3 months ago

Unlock the full Endpoints experience for your company — and support our mission of independent biopharma reporting

2 months ago

Publisher's note

[Video] Celebrating trial failures, changing the culture and allying with California dreamers: R&D chief Hal Barron ...

4 months ago

Peer review See all

Feb

21

Antonio Gualberto starts post-Kura career at Eisai subsidiary H3; eFFECTOR co-founder Siegfried Reich jumps to Turning Point

Feb

14

Palleon's first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO

Feb

7

Craig Basson tells us why he leapt from NIBR to Boston Pharma; Ex-BMS Partner CytomX finds new CMO in Allison Hannah

Jan

31

Moderna woos trial vet Melanie Ivarsson to the senior R&D team; Ex-Roche CMO Sandra Horning joins Gilead board

Jan

24

Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron's CBO hops ship to lead startup

R&D channel feed

3 days ago

Biogen touts new evidence from the gene therapy company it wagered $800M on

A year ago, Biogen made a big bet on a small gene therapy company. Now they have new evidence one of their therapies could work. In a first-in-human study on young men with a genetic ...

READ MORE

UPDATED: NIH-partnered Moderna ships off its PhI-ready coronavirus vaccine candidate to a sea of uncertainty

3 days ago

UPDATED: NGM Bio takes leap forward in crowded NASH field

4 days ago

latest in R&D

Acacia Pharma's twice spurned drug finally makes the FDA cut

Yesterday

UPDATED: Following US, China hospital efforts, Gilead plots its own PhIII trials for closely watched Covid-19 drug

Yesterday

One less rival for Immunovant, as Alexion abandons FcRn inhibitor

2 days ago

First US Covid-19 trials set to get underway in Nebraska and Washington, backed by NIH

3 days ago

Novartis gets a boost in blockbuster multiple sclerosis race with Roche

4 days ago

see latest stories

Pharma channel feed

4 days ago

Sanofi outlines big API plans as coronavirus outbreak reportedly threatens shortage of 150 drugs

As the world becomes increasingly dependant on Asia for the ingredients of its medicines, Sanofi sees business to be done in Europe. The French drugmaker said it's creating the world's ...

READ MORE

Mallinckrodt, once the nation’s largest oxycodone producer, announces tentative $1.6B settlement

3 days ago

UPDATED: Novartis' plans to wrestle Eylea market share take a hit as Beovu is linked to safety concerns

3 days ago

latest in Pharma

The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B

5 days ago

Esperion's goldilocks cholesterol fighter wins FDA approval — will its 'traditional' pricing approach spur adoption?

6 days ago

Pharmacogenetics: FDA releases table of gene-drug interactions

Last week

Don't let AbbVie fool FTC with an easy divestiture, plead critics in latest attack on $63B Allergan buyout

Last week

Austedo, Teva's bright spot as it executes turnaround, fails two Tourette's trials

Last week

see latest stories